Fewer than half of Americans trust the FDA and CDC to do their job, poll finds
Fewer than half of Americans trust in federal health agencies like the Food and Drug Administration and Centers for Disease Control and Prevention to do crucial parts of their job under the Trump administration.
Just 42 percent of more than 1,000 people surveyed in a new poll from the non-profit KFF think federal health agencies are effectively able to respond to infectious disease outbreaks. Furthermore, only 45 percent are confident that they could ensure the safety and effectiveness of vaccines approved for use in the U.S., and 46 percent believe that these and other health agencies can ensure prescription drugs are safe and effective for public usage.
'There are remarkably low levels of trust in the nation's scientific agencies, shaped by partisan perspectives, and that presents a real danger for the country if and when another pandemic hits,' KFF CEO Drew Altman said in a statement.
The findings come amid heightened vaccine hesitancy that has helped to fuel the recent and deadly West Texas measles outbreak, and moves made by Health and Human Services Secretary Robert F. Kennedy, Jr. in support of alternate treatments and review established science.
Less than half of Americans say they trust in federal health agencies to do critical parts of their job. A new poll comes following a major overhaul of the country's science and research programs (Getty Images)
While most adults said that they were at least 'somewhat confident' in the safety of routine vaccines — including for the measles (84 percent) and the flu (74 percent) — that number drops significantly when questioned about the Covid vaccine. Indeed, only 56 percent of adults say that are at least 'somewhat confident' that it is safe.
One of the reasons behind the lack of confidence is that 60 percent of the public, including Democrat voters, say that the CDC and FDA aren't paying close enough attention to science when making decisions under the Trump administration. Less than a third of respondents said they had confidence in the agencies to act independently without interference from outside groups.
Vaccine hesitancy has contributed to the West Texas measles outbreak. The state has seen nearly 700 cases (Getty Images)
'In addition, at least three in ten say these agencies are paying 'too much attention' to the beliefs of officials running the agencies (34 percent) and the interests of pharmaceutical companies (30 percent) when making vaccine-related decisions,' KFF said.
Many of the responses fell along party lines. For example, Democrats were more likely to say that they have 'some' trust in government health agencies. While 87 percent of Democrats were at least 'somewhat confident' in the Covid vaccines' safety - just 30 percent of Republicans said the same.
But, for Democrats, trust in the agencies to provide vaccine information is declining: falling by double digits since 2023. For Republicans, that's increased by 10 percentage points.
'While Democrats are still more likely than Republicans to trust either the CDC or FDA as a source of vaccine information, the shifts in trust mark a notable reversal in partisan trends first observed during the start of the Covid pandemic,' said KFF.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Who's in charge? CDC's leadership 'crisis' apparent amid new COVID-19 vaccine guidance
WASHINGTON (AP) — There was a notable absence last week when U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced in a 58-second video that the government would no longer endorse the COVID-19 vaccine for healthy children or pregnant women. The director of the Centers for Disease Control and Prevention — the person who typically signs off on federal vaccine recommendations — was nowhere to be seen. The CDC, a $9.2 billion-a-year agency tasked with reviewing life-saving vaccines, monitoring diseases and watching for budding threats to Americans' health, is without a clear leader. 'I've been disappointed that we haven't had an aggressive director since — February, March, April, May — fighting for the resources that CDC needs,' said Dr. Robert Redfield, who served as CDC director under the first Trump administration and supported Kennedy's nomination as the nation's health secretary. $9.2 billion-a-year agency without leader as nomination awaits The leadership vacuum at a foremost federal public health agency has existed for months, after President Donald Trump suddenly withdrew his first pick for CDC director in March. A hearing for his new nominee — the agency's former acting director Susan Monarez — has not been scheduled because she has not submitted all the paperwork necessary to proceed, according to a spokesman for Sen. Bill Cassidy, R-La., who will oversee the nomination. HHS did not answer written questions about Monarez's nomination, her current role at the CDC or her salary. An employee directory lists Monarez, a longtime government employee, as a staffer for the NIH under the Advanced Research Projects Agency for Health. Redfield described Kennedy as 'very supportive' of Monarez's nomination. Instead, a lawyer and political appointee with no medical experience is 'carrying out some of the duties' of director at the agency that for seven decades has been led by someone with a medical degree. Matthew Buzzelli, who is also the chief of staff at the CDC, is 'surrounded by highly qualified medical professionals and advisors to help fulfill these duties as appropriate,' Andrew Nixon, an HHS spokesperson said in a statement. Adding to the confusion was an employee-wide email sent last week that thanked 'new acting directors who shave stepped up to the plate." The email, signed by Monarez, listed her as the acting director. It was was sent just days after Kennedy said at a Senate hearing that Monarez had been replaced by Buzzelli. The lack of a confirmed director will be a problem if a public health emergency such as the COVID-19 pandemic or a rapid uptick in measles cases hits, said Michael Osterholm, an epidemiologist at the University of Minnesota. 'CDC is a crisis, waiting for a crisis to happen,' said Osterholm. 'At this point, I couldn't tell you for the life of me who was going to pull what trigger in a crisis situation." An acting director rarely seen, and stalled decisions At CDC headquarters in Atlanta, employees say Monarez was rarely heard from between late January – when she was appointed acting director – and late March, when Trump nominated her. She also has not held any of the 'all hands' meetings that were customary under previous CDC chiefs, according to several staffers. One employee, who insisted on anonymity because they were not authorized to speak to the media and fears being fired if identified said Monarez has been almost invisible since her nomination, adding that her absence has been cited by other leaders as an excuse for delaying action. The situation already has led to confusion. In April, a 15-member CDC advisory panel of outside experts met to discuss vaccine policy. The panel makes recommendations to the CDC Director, who routinely signs off on them. But it was unclear during the meeting who would be reviewing the panel's recommendations, which included the expansion of RSV vaccinations for adults and a new combination shot as another option to protect teens against meningitis. HHS officials said the recommendations were going to Buzzelli, but then weeks passed with no decision. A month after the meeting ended, the CDC posted on a web site that Kennedy had signed off on recommendations for travelers against chikungunya, a viral disease transmitted to humans by mosquitos. But there continues to be no word about a decision about the other vaccine recommendations. Controversial COVID-19 vaccine recommendations bypassed CDC panel The problem was accentuated again last week, when Kennedy rolled out recommendations for the COVID-19 vaccine saying they were no longer recommended for healthy children or pregnant women, even though expectant mothers are considered a high-risk group if they contract the virus. Kennedy made the surprise announcement without input from the CDC advisory panel that has historically made recommendations on the nation's vaccine schedule. The CDC days later posted revised guidance that said healthy kids and pregnant women may get the shots. Nixon, the HHS spokesman, said CDC staff were consulted on the recommendations, but would not provide staffer's names or titles. He also did not provide the specific data or research that Kennedy reviewed to reach his conclusion on the new COVID-19 recommendations, just weeks after he said that he did not think 'people should be taking medical advice' from him. 'As Secretary Kennedy said, there is a clear lack of data to support the repeat booster strategy in children,' Nixon said in a statement. Research shows that pregnant women are at higher risk of severe illness, mechanical ventilation and death, when they contract COVID-19 infections. During the height of the pandemic, deaths of women during pregnancy or shortly after childbirth soared to their highest level in 50 years. Vaccinations also have been recommended for pregnant women because it passes immunity to newborns who are too young for vaccines and also vulnerable to infections. Nixon did not address a written question about recommendations for pregnant women. Kennedy's decision to bypass the the advisory panel and announce new COVID-19 recommendations on his own prompted a key CDC official who works with the committee – Dr. Lakshmi Panagiotakopoulos – to announce her resignation last Friday. 'My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role,' she wrote in an email seen by an Associated Press reporter. Signs are mounting that the CDC has been 'sidelined' from key decision-making under Kennedy's watch, said Dr. Anand Parekh, the chief medical adviser for The Bipartisan Policy Center. 'It's difficult to ascertain how we will reverse the chronic disease epidemic or be prepared for myriad public health emergencies without a strong CDC and visible, empowered director,' Parekh said. 'It's also worth noting that every community in the country is served by a local or state public health department that depends on the scientific expertise of the CDC and the leadership of the CDC director.'
New York Times
14 minutes ago
- New York Times
MRNA, Used in Covid Shots, May Help Rid the Body of H.I.V.
The technology that powered Covid vaccines may also lead scientists to a cure for H.I.V. Using mRNA, Australian researchers said they were able to trick the virus to come out of hiding, a crucial step in ridding the body of it entirely. The research, published last week in Nature Communications, is still preliminary, and so far, has been shown to be successful only in a lab. But it suggests that mRNA has potential far beyond its use in vaccines as a means to deliver therapies against stubborn adversaries. Short for messenger RNA, mRNA is a set of instructions for a gene. In the case of Covid vaccines, the instructions were for a piece of the coronavirus. In the new study, they are for molecules key to targeting H.I.V. 'mRNA is just this miraculous — I really do think miraculous — tool to deliver things that you want into places that were not possible before,' said Dr. Sharon Lewin, director of the Cumming Global Center for Pandemic Therapeutics in Melbourne, who led the study. Vaccines deploying mRNA instruct the body to produce a fragment of the virus, which then sets off the body's immune response. In the United States, the shots were initially hailed for turning back the pandemic, then viewed by some with suspicion and fear. Some officials, including Health Secretary Robert F. Kennedy Jr., have falsely said that they are highly dangerous and even deadly. Last week, the Department of Health and Human Services sought to limit the vaccine's availability to pregnant women, children and healthy younger adults. The administration also canceled a nearly $600 million contract with the drugmaker Moderna to develop an mRNA shot for humans against bird flu. Want all of The Times? Subscribe.
Axios
15 minutes ago
- Axios
Senate GOP eyes Medicare cuts with Trump's blessing
President Trump gave Republican senators a green light to explore ways to save money on Medicare during a meeting at the White House, senators said Thursday. Why it matters: Changes to save money on Medicaid have already proven contentious with some Republicans. Medicare could open a new can of worms. "The president is willing to eliminate any waste, fraud and abuse anywhere," Sen. Ron Johnson (R-Wisc.) told Axios about the White House meeting Wednesday night that he attended, "which opens up Medicare, as well," he added. "What the president made clear is he does not want to see any cuts to beneficiaries, but to go after... the waste, fraud and abuse," said Sen. Steve Daines (R-Mont.), clarifying that Trump opened up Medicare as an option at the meeting. Politico first reported on the Medicare discussions. What to watch: One possibility being floated is a bill from Sen. Bill Cassidy (R-La.), which would get savings from the Medicare Advantage program. The measure would crack down on an insurer practice known as "upcoding," where health insurers classify patients as sicker in order to secure higher government payments. Cracking down on the practice has some support from Democrats as well, but would be sure to draw the opposition of the health insurance industry.
